Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

Algernon Pharmaceuticals Inc

Company price
0.26 USD 0.00(0%)
Last update at 2026-11-13T14:30:00Z
Market Cap
0.22M

Momentum Score

…

Algernon Health Inc. operates as a clinical stage pharmaceutical development company in Canada and Australia. The company focuses on developing the therapeutic drugs in the areas of non-alcoholic steatohepatitis, liver disease, chronic kidney disease, and stroke program. Its pipeline includes repirinast for the treatment of chronic kidney disease; and N,N-Dimethyltryptamine for the treatment of strokes and traumatic brain injuries. The company was formerly known as Algernon Pharmaceuticals Inc. and changed its name to Algernon Health Inc. in October 2025. Algernon Health Inc. was incorporated in 2015 and is headquartered in Vancouver, Canada.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.26
Low
0.26
High
52 Week Price Range
0.00
Low
0.72
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Algernon Pharmaceuticals Inc is a clinical-stage pharmaceutical company developing small-molecule therapeutics. Long-term growth drivers may include progress in clinical programs, regulatory approvals, and partnering or licensing that could advance and commercialize pipeline assets. Investors may find the company attractive for upside tied to clinical milestones and potential pipeline expansion.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.26
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
-
ROE
-90.47%
Net Debt
-
ROCE
-63.73%
Diluted EPS TTM
-0.51

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-08-31 2024-08-31 2023-08-31 2022-08-31 2021-08-31
Type yearly yearly yearly yearly yearly
Date 2025-08-31 2024-08-31 2023-08-31 2022-08-31 2021-08-31
Income before tax -1.72M -0.50M -6.78M -6.05M -7.73M
Net income -1.72M -0.50M -6.78M -6.05M -7.73M
Selling general administrative 1.64M 1.76M 4.15M 3.73M 3.25M
Reconciled depreciation 0.05M 0.03M 0.05M 0.03M -
Ebit - - - -5.74M -7.88M
Ebitda - - - -6.02M -8.05M
Operating income -1.72M -2.41M -5.24M -6.06M -8.05M
Interest expense - - - - 0.00M
Interest income 0.00M 0.00M 0.00M 0.00M 0.01M
Net interest income 0.00M 0.00M 0.00M 0.00M 0.01M
Total revenue 0.00M 0.00M 0.00M 0.00M 0.00M
Total operating expenses 1.72M 2.41M 5.24M 6.06M 8.05M
Total other income expense net - 1.91M -1.54M - 0.31M
Net income from continuing ops -1.72M -0.50M -6.78M -6.05M -7.73M
Net income applicable to common shares - - - -6.05M -7.73M
Breakdown 2025-08-31 2024-08-31 2023-08-31 2022-08-31 2021-08-31
Type yearly yearly yearly yearly yearly
Date 2025-08-31 2024-08-31 2023-08-31 2022-08-31 2021-08-31
Total assets 4.88M 3.94M 4.19M 8.14M 10.14M
Intangible assets 4.29M 3.18M 3.80M 5.26M 5.17M
Total liab 2.18M 1.78M 2.72M 2.52M 1.02M
Total stockholder equity 2.70M 2.17M 1.47M 5.62M 9.12M
Common stock - - - 27.12M 25.85M
Capital stock 30.17M 29.56M 28.15M 27.12M 25.85M
Retained earnings -30.56M -30.76M -30.79M -25.19M -23.55M
Other assets - - - 0.06M 0.06M
Cash 0.18M 0.60M 0.13M 1.41M 2.41M
Total current liabilities 2.18M 1.78M 2.72M 2.52M 1.02M
Other stockholder equity - - - 3.70M 6.81M
Total current assets 0.55M 0.74M 0.34M 2.83M 4.91M
Net tangible assets - - - 0.37M 3.94M
Net receivables - - - 0.67M 2.29M
Accounts payable - - - 2.24M 1.02M
Non currrent assets other 0.03M 0.03M 0.06M 0.06M 0.06M
Non current assets total 4.32M 3.21M 3.85M 5.31M 5.23M
Breakdown 2025-08-31 2024-08-31 2023-08-31 2022-08-31 2021-08-31
Type yearly yearly yearly yearly yearly
Date 2025-08-31 2024-08-31 2023-08-31 2022-08-31 2021-08-31
Investments - 2.28M -0.06M -0.14M -0.12M
Change to liabilities - - - 1.52M 0.37M
Total cashflows from investing activities - - - -0.14M -0.12M
Total cash from financing activities 0.59M 0.90M 1.33M 2.06M 4.25M
Change to operating activities - - - -0.55M 0.18M
Net income -1.72M -0.50M -6.78M -6.05M -7.73M
Change in cash -0.42M 0.47M -1.28M -1.00M -3.71M
Begin period cash flow 0.60M 0.13M 1.41M 2.41M 6.12M
End period cash flow 0.18M 0.60M 0.13M 1.41M 2.41M
Total cash from operating activities -1.16M -2.71M -2.55M -2.91M -7.82M
Issuance of capital stock 0.59M 0.89M 1.23M 2.06M 2.69M
Depreciation 0.05M 0.03M 0.05M 0.03M 0.03M
Change to account receivables -0.00M 0.08M 0.57M 1.61M -1.15M
Other cashflows from financing activities - - - 0.79M 1.18M
Change to netincome - - - 0.52M 0.51M
Capital expenditures 0.02M 0.08M 0.06M 0.14M 0.12M
Change in working capital 0.26M -0.62M 1.27M 2.58M -0.60M
Stock based compensation 0.20M 0.29M 1.26M 0.53M 0.83M
Other non cash items - -0.25M 0.04M - -0.31M
Free cash flow -1.18M -2.79M -2.61M -3.06M -7.95M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to EBITDA (x)
AGNPF
Algernon Pharmaceuticals Inc
-
-%
0.26 - - - 1.81 -0.61
NVO
Novo Nordisk A/S
0.98
2.41%
41.63 41.58 31.15 2.13 32.99 4.70
VRTX
Vertex Pharmaceuticals Inc
-4.02
0.74%
538.60 30.22 24.27 10.36 6.50 24.66
REGN
Regeneron Pharmaceuticals Inc
4.28
0.45%
955.47 29.07 20.12 7.57 3.82 19.42
ARGNF
argenx SE
64.70
7.19%
965.00 45.77 31.25 13.84 7.12 36.06

Profile*

Algernon Pharmaceuticals Inc

Algernon Health Inc. operates as a clinical stage pharmaceutical development company in Canada and Australia. The company focuses on developing the therapeutic drugs in the areas of non-alcoholic steatohepatitis, liver disease, chronic kidney disease, and stroke program. Its pipeline includes repirinast for the treatment of chronic kidney disease; and N,N-Dimethyltryptamine for the treatment of strokes and traumatic brain injuries. The company was formerly known as Algernon Pharmaceuticals Inc. and changed its name to Algernon Health Inc. in October 2025. Algernon Health Inc. was incorporated in 2015 and is headquartered in Vancouver, Canada.

601 West Broadway, Vancouver, BC, Canada, V5Z 4C2

604 398 4175

Name Title Year Born
Mr. Christopher J. Moreau CEO & Director 1965
Dr. Christopher Bryan Ph.D. VP of Research & Operations 1983
Mr. James F. Kinley C.A., CPA Chief Financial Officer 1978
Dr. Christopher Bryan Ph.D. Vice President of Research & Operations 1983
Mr. James F. Kinley C.A., CPA CFO & Corporate Secretary 1978

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…